184 related articles for article (PubMed ID: 35677634)
41. Identification of long noncoding RNAs biomarkers for diagnosis and prognosis in patients with colon adenocarcinoma.
Huang W; Liu Z; Li Y; Liu L; Mai G
J Cell Biochem; 2019 Mar; 120(3):4121-4131. PubMed ID: 30269368
[TBL] [Abstract][Full Text] [Related]
42. Identification of a novel glycolysis-related gene signature for predicting the survival of patients with colon adenocarcinoma.
Yi K; Wu J; Tang X; Zhang Q; Wang B; Wang F
Scand J Gastroenterol; 2022 Feb; 57(2):214-221. PubMed ID: 34644216
[TBL] [Abstract][Full Text] [Related]
43. N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer.
Jiao J; Jiang L; Luo Y
Recent Pat Anticancer Drug Discov; 2021; 16(3):407-416. PubMed ID: 34137363
[TBL] [Abstract][Full Text] [Related]
44. Immune infiltration-related N6-methyladenosine RNA methylation regulators influence the malignancy and prognosis of endometrial cancer.
Ma J; Yang D; Ma XX
Aging (Albany NY); 2021 Jun; 13(12):16287-16315. PubMed ID: 34230220
[TBL] [Abstract][Full Text] [Related]
45. Comprehensive analysis of m6A regulators prognostic value in prostate cancer.
Ji G; Huang C; He S; Gong Y; Song G; Li X; Zhou L
Aging (Albany NY); 2020 Jul; 12(14):14863-14884. PubMed ID: 32710725
[TBL] [Abstract][Full Text] [Related]
46. Gene expression and methylation profiles identified CXCL3 and CXCL8 as key genes for diagnosis and prognosis of colon adenocarcinoma.
Zhao QQ; Jiang C; Gao Q; Zhang YY; Wang G; Chen XP; Wu SB; Tang J
J Cell Physiol; 2020 May; 235(5):4902-4912. PubMed ID: 31709538
[TBL] [Abstract][Full Text] [Related]
47. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma.
Xu F; Guan Y; Ma Y; Xue L; Zhang P; Yang X; Chong T
Aging (Albany NY); 2021 Apr; 13(8):11919-11941. PubMed ID: 33952721
[TBL] [Abstract][Full Text] [Related]
48. High MICAL-L2 expression and its role in the prognosis of colon adenocarcinoma.
Yang Y; Ye F; Xia T; Wang Q; Zhang Y; Du J
BMC Cancer; 2022 May; 22(1):487. PubMed ID: 35501725
[TBL] [Abstract][Full Text] [Related]
49. Identification and validation of a prognostic risk-scoring model based on sphingolipid metabolism-associated cluster in colon adenocarcinoma.
Yuan Q; Zhang W; Shang W
Front Endocrinol (Lausanne); 2022; 13():1045167. PubMed ID: 36518255
[TBL] [Abstract][Full Text] [Related]
50. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients.
Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357
[TBL] [Abstract][Full Text] [Related]
51. The analysis of N6-methyladenosine regulators impacting the immune infiltration in clear cell renal cell carcinoma.
Li J; Cao J; Liang C; Deng R; Li P; Tian J
Med Oncol; 2022 Jan; 39(4):41. PubMed ID: 35092501
[TBL] [Abstract][Full Text] [Related]
52. Comprehensive analysis of microRNA/mRNA signature in colon adenocarcinoma.
Wang JY; Wang CL; Wang XM; Liu FJ
Eur Rev Med Pharmacol Sci; 2017 May; 21(9):2114-2129. PubMed ID: 28537673
[TBL] [Abstract][Full Text] [Related]
53. In silico development and clinical validation of novel 8 gene signature based on lipid metabolism related genes in colon adenocarcinoma.
Jiang C; Liu Y; Wen S; Xu C; Gu L
Pharmacol Res; 2021 Jul; 169():105644. PubMed ID: 33940186
[TBL] [Abstract][Full Text] [Related]
54. Comprehensive analysis of the differential expression and prognostic value of COL1A2 in colon adenocarcinoma.
Jin JJ; Zheng T; Xu XX; Zheng L; Li FY; Li XX; Zhou L
Aging (Albany NY); 2022 Sep; 14(18):7390-7407. PubMed ID: 36057263
[TBL] [Abstract][Full Text] [Related]
55. METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N
Wan W; Ao X; Chen Q; Yu Y; Ao L; Xing W; Guo W; Wu X; Pu C; Hu X; Li Z; Yao M; Luo D; Xu X
Mol Cancer; 2022 Feb; 21(1):60. PubMed ID: 35197058
[TBL] [Abstract][Full Text] [Related]
56. Integrative Analysis of m6A RNA Methylation Regulators and the Tumor Immune Microenvironment in Non-Small-Cell Lung Cancer.
Zhu J; Jiang Y; Wang T; Wu A; Zhou T; Zhang A; Tang Y; Shen Z; Wang J; Zhou H; Shi J; Chen J
Dis Markers; 2022; 2022():2989200. PubMed ID: 35186164
[TBL] [Abstract][Full Text] [Related]
57. Identifying tumor antigens and immuno-subtyping in colon adenocarcinoma to facilitate the development of mRNA vaccine.
Tan H; Yu T; Liu C; Wang Y; Jing F; Ding Z; Liu J; Shi H
Cancer Med; 2022 Dec; 11(23):4656-4672. PubMed ID: 35593226
[TBL] [Abstract][Full Text] [Related]
58. Establishment and validation of a prognostic model based on HRR-related lncRNAs in colon adenocarcinoma.
Tang X; Lin Y; He J; Luo X; Liang J; Zhu X; Li T
World J Surg Oncol; 2022 Mar; 20(1):74. PubMed ID: 35264195
[TBL] [Abstract][Full Text] [Related]
59. Screening and Identification of Differentially Expressed Genes Expressed among Left and Right Colon Adenocarcinoma.
Han J; Zhang X; Yang Y; Feng L; Wang GY; Zhang N
Biomed Res Int; 2020; 2020():8465068. PubMed ID: 32420374
[TBL] [Abstract][Full Text] [Related]
60. Development and validation of a novel N6-methyladenosine (m6A)-related multi- long non-coding RNA (lncRNA) prognostic signature in pancreatic adenocarcinoma.
Yuan Q; Ren J; Li L; Li S; Xiang K; Shang D
Bioengineered; 2021 Dec; 12(1):2432-2448. PubMed ID: 34233576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
